PLN9.04 0.0 0.0%
Last Trade - 01/03/21
| Market Cap | ÂŁ107.5m |
| Enterprise Value | ÂŁ109.9m |
| Revenue | ÂŁ7.79m |
| Position in Universe | 165th / 790 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020E | 2021E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 33.6 | 42.6 | 36.3 | 31.4 | 32.3 | 39.1 | +3.1% | ||||
| -78.0 | ||||||||||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Biomed Lublin Wytwornia Surowic i Szczepionek SA is a Poland-based company engaged in the pharmaceuticals industry.
| Last Annual | December 31st, 2019 |
| Last Interim | September 30th, 2020 |
| Incorporated | December 13, 2010 |
| Public Since | July 29, 2011 |
| No. of Shareholders: | n/a |
| No. of Employees: | 230 |
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Index | |
| Exchange | Warsaw Stock Exchange |
| Shares in Issue | 62,260,410 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | ul Uniwersytecka 10, LUBLIN, 20-029, Poland |
| Web | http://www.biomed.lublin.pl |
| Phone | +48 81 5338221 |
| Contact | () |
| Auditors | UHY ECA Audyt Sp. Zoo SP. k. |
As of 01/03/21, shares in Biomed Lublin Wytwornia Surowic i Szczepionek SA are trading at PLN9.04, giving the company a market capitalisation of ÂŁ107.5m. This share price information is delayed by 15 minutes.
Shares in Biomed Lublin Wytwornia Surowic i Szczepionek SA are currently trading at PLN9.04 and the price has moved by 0.577k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Biomed Lublin Wytwornia Surowic i Szczepionek SA price has moved by 0.538k% over the past year.
There are no analysts currently covering Biomed Lublin Wytwornia Surowic i Szczepionek SA.
Biomed Lublin Wytwornia Surowic i Szczepionek SA is scheduled to issue upcoming financial results on the following dates:
Biomed Lublin Wytwornia Surowic i Szczepionek SA does not currently pay a dividend.
Biomed Lublin Wytwornia Surowic i Szczepionek SA does not currently pay a dividend.
Biomed Lublin Wytwornia Surowic i Szczepionek SA does not currently pay a dividend.
To buy shares in Biomed Lublin Wytwornia Surowic i Szczepionek SA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Biomed Lublin Wytwornia Surowic i Szczepionek SA are currently trading at PLN9.04, giving the company a market capitalisation of ÂŁ107.5m.
Here are the trading details for Biomed Lublin Wytwornia Surowic i Szczepionek SA:
Based on an overall assessment of its quality, value and momentum, Biomed Lublin Wytwornia Surowic i Szczepionek SA is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We were not able to load any forecast data for Biomed Lublin Wytwornia Surowic i Szczepionek SA.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Biomed Lublin Wytwornia Surowic i Szczepionek SA. Over the past six months, the relative strength of its shares against the market has been -56.82%. At the current price of PLN9.04, shares in Biomed Lublin Wytwornia Surowic i Szczepionek SA are trading at -28.29% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Biomed Lublin Wytwornia Surowic i Szczepionek SA PE ratio based on its reported earnings over the past 12 months is 0.302k. The shares are currently trading at PLN9.04.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Biomed Lublin Wytwornia Surowic i Szczepionek SA's management team is headed by:
Here are the top five shareholders of Biomed Lublin Wytwornia Surowic i Szczepionek SA based on the size of their shareholding:
